These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 34049982)

  • 41. 18F-FDG PET/CT for early prediction of response to neoadjuvant lapatinib, trastuzumab, and their combination in HER2-positive breast cancer: results from Neo-ALTTO.
    Gebhart G; Gámez C; Holmes E; Robles J; Garcia C; Cortés M; de Azambuja E; Fauria K; Van Dooren V; Aktan G; Coccia-Portugal MA; Kim SB; Vuylsteke P; Cure H; Eidtmann H; Baselga J; Piccart M; Flamen P; Di Cosimo S
    J Nucl Med; 2013 Nov; 54(11):1862-8. PubMed ID: 24092940
    [TBL] [Abstract][Full Text] [Related]  

  • 42. PIK3CA Mutational Status Is Associated with High Glycolytic Activity in ER+/HER2- Early Invasive Breast Cancer: a Molecular Imaging Study Using [
    Magometschnigg H; Pinker K; Helbich T; Brandstetter A; Rudas M; Nakuz T; Baltzer P; Wadsak W; Hacker M; Weber M; Dubsky P; Filipits M
    Mol Imaging Biol; 2019 Oct; 21(5):991-1002. PubMed ID: 30652258
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Synthesis of 11 beta-[18F]fluoro-5 alpha-dihydrotestosterone and 11 beta-[18F]fluoro-19-nor-5 alpha-dihydrotestosterone: preparation via halofluorination-reduction, receptor binding, and tissue distribution.
    Choe YS; Lidström PJ; Chi DY; Bonasera TA; Welch MJ; Katzenellenbogen JA
    J Med Chem; 1995 Mar; 38(5):816-25. PubMed ID: 7877147
    [TBL] [Abstract][Full Text] [Related]  

  • 44. The maximum standardized uptake value of metastatic site in 18 F-FDG PET/CT predicts molecular subtypes and survival in metastatic breast cancer: An Izmir Oncology Group study.
    Cokmert S; Tanriverdi O; Karapolat I; Demir L; Bayoglu V; Can A; Akyol M; Yilmaz Y; Oktay Tarhan M
    J BUON; 2016; 21(6):1410-1418. PubMed ID: 28039701
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Head-to-Head Evaluation of
    Ulaner GA; Jhaveri K; Chandarlapaty S; Hatzoglou V; Riedl CC; Lewis JS; Mauguen A
    J Nucl Med; 2021 Mar; 62(3):326-331. PubMed ID: 32680923
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Synthesis and basic evaluation of 7α-(3-[
    Okamoto M; Naka K; Ishiwata K; Shimizu I; Toyohara J
    Ann Nucl Med; 2017 Jan; 31(1):53-62. PubMed ID: 27680022
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Phase I study of ARN-509, a novel antiandrogen, in the treatment of castration-resistant prostate cancer.
    Rathkopf DE; Morris MJ; Fox JJ; Danila DC; Slovin SF; Hager JH; Rix PJ; Chow Maneval E; Chen I; Gönen M; Fleisher M; Larson SM; Sawyers CL; Scher HI
    J Clin Oncol; 2013 Oct; 31(28):3525-30. PubMed ID: 24002508
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Selective androgen receptor modulators (SARMs) have specific impacts on the mouse uterus.
    Simitsidellis I; Esnal-Zuffiaure A; Kelepouri O; O'Flaherty E; Gibson DA; Saunders PTK
    J Endocrinol; 2019 Sep; 242(3):227-239. PubMed ID: 31319382
    [TBL] [Abstract][Full Text] [Related]  

  • 49. 18F-fluoromisonidazole PET/CT: a potential tool for predicting primary endocrine therapy resistance in breast cancer.
    Cheng J; Lei L; Xu J; Sun Y; Zhang Y; Wang X; Pan L; Shao Z; Zhang Y; Liu G
    J Nucl Med; 2013 Mar; 54(3):333-40. PubMed ID: 23401605
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Diagnostic accuracy and safety of 16α-[
    Chae SY; Ahn SH; Kim SB; Han S; Lee SH; Oh SJ; Lee SJ; Kim HJ; Ko BS; Lee JW; Son BH; Kim J; Ahn JH; Jung KH; Kim JE; Kim SY; Choi WJ; Shin HJ; Gong G; Lee HS; Lee JB; Moon DH
    Lancet Oncol; 2019 Apr; 20(4):546-555. PubMed ID: 30846327
    [